

**Press release Delphi 01/04/2018:**

**Delphi advisor to Immunicum in connection with rights issue**

Advokatfirman Delphi has acted as legal advisor to Immunicum AB in connection with a rights issue of approximately SEK 200 million.

Immunicum is a biotechnology company advancing a novel immuno-oncology treatment against a range of solid tumors. The company aims to advance therapeutic cancer treatments at least through clinical phase II trials and then license the product candidates to major pharmaceutical or biotech companies.

Pareto Securities AB has acted as financial advisor in connection with the rights issue.

For more information, see Immunicum's press release: [www.imminicum.se](http://www.imminicum.se)

Delphi's team consisted mainly of responsible partner Mats Dahlberg, Jonas Ingvarsson and Jenny Lindén. In addition, a large number of Delphi lawyers have been involved in the work.

Contact:

Mats Dahlberg  
Partner/Advokat  
Delphi  
Ph. +46 709 25 25 94  
email: [mats.dahlberg@delphi.se](mailto:mats.dahlberg@delphi.se)

**Delphi** is one of the top commercial law firms in Sweden. We help our clients with mergers and acquisitions. We advise them on matters of banking, finance and capital markets. We represent clients in court and in arbitration and are acknowledged as being extremely competent in public procurement, environmental law and real estate law.

Many of us are specialists in high-tech fields such as IT, intellectual property and life science. Our drive and our interest in technology and business probably explain, in part, our success. We are often praised for our commercial sense and our ability to understand the client's business.

Our clients are to be found primarily in Scandinavia, Europe and North America. We also co-operate with law firms globally and regularly assist clients on international matters. We have a total workforce of approximately 185, of which more than 120 are lawyers. We have offices in Stockholm, Göteborg, Malmö, Linköping and Norrköping.